We assessed the signaling pathway activation of 50 HALLMARK typical tumor pathways and observed that patients in the high-risk group contained the activation pathways of apical junction, epithelial mesenchymal transition, WNT/beta-catenin signaling, as well as immune-associated pathways, including IL2/STAT5, IL6/JAK/STAT3, Notch signaling and the inflammatory response pathway (Figure 7A, Supplementary Table S1). This evidence concerns the gene CTNNB1 and neoplasm.